Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand

Inclusion Criteria for rfMDA: * Index cases: Presented as a confirmed malaria case to an intervention health facility or village malaria worker, and lives in a village within a selected intervention subdistrict, or worked or spent at least one night at a forest or forest-fringe site in the past 30 days located within an intervention subdistrict * Village residents: Lives in a village within a selected intervention subdistrict area and in one of the five households closest to the residence of an index case of malaria * Co-worker/traveler referral: Worked or traveled and spent at least one night in forest in past 30 days in same location within an intervention subdistrict as an index case of malaria * All participants: Willing and available to participate in the study and informed consent for participant under the age of 18 will be provided by the parent or guardian. Participants for focus group discussions (FGDs) and key informant interviews (KIIs); 18 years of age or older Exclusion Criteria: • For rfMDA: * Previous participation in the study as a result of any rfMDA event in the past 30 days * Individuals with severe disease or drug contra-indications will be excluded from the treatment component only * Artesunate-Mefloquine: Pregnancy in the first trimester, or known drug allergy * Use of Mefloquine within 60 days of first treatment prior to enrollment date.